Nucleocytoplasmic transport is a fundamental cellular process that regulates the movement of molecules between the cytoplasm and nucleus through the nuclear pore complex (NPC). This pathway is essential for maintaining cellular homeostasis, gene expression, and protein quality control. Recent research has revealed that defects in nucleocytoplasmic transport are a central mechanism in the pathogenesis of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and Parkinson's disease (PD).
The nuclear envelope separates the nucleus from the cytoplasm, and the NPC is the sole gateway for macromolecular transport between these compartments. The NPC comprises approximately 30 different nucleoporins (NUPs) that form a selective barrier allowing passive diffusion of small molecules while facilitating active transport of larger proteins and RNA complexes[1].
flowchart TD
A[Nuclear Pore Complex] --> B[Nuclear Basket]
A --> C[Central Channel]
A --> D[Cytoplasmic Filaments]
B --> E[NUP153]
B --> E2[NUP50]
C --> F[NUP93]
C --> F2[NUP205]
C --> F3[NUP188]
C --> F4[NUP35]
D --> G[NUP358]
D --> G2[NUP214]
F --> H[FG-Nup Repeats]
H --> I[Hydrophobic Interactions]
I --> J[ Karyopherins]
J --> K[Importin α/β]
J --> K2[Exportins]
K --> L[Protein Import]
K2 --> M[RNA Export]
L --> N[Nuclear Localization Signal]
M --> O[mRNA Export]
style A fill:#90EE90
style J fill:#87CEEB
style N fill:#FF6B6B
style O fill:#FF6B6B
| Protein |
Gene |
Role in Transport |
| Importin α |
KPNA1-7 |
Adapter protein for NLS recognition |
| Importin β |
KPNB1 |
Karyopherin for nuclear import |
| Exportin 1 |
XPO1/CRM1 |
Primary RNA/protein export receptor |
| Exportin t |
EXPORT1 |
tRNA export |
| CAS |
CASR |
Importin α recycling |
| RanGAP1 |
RANGAP1 |
GTPase activating protein |
| RanGEF |
RCC1 |
Ran GTP loading in nucleus |
| NUP98 |
NUP98 |
FG-repeat nucleoporin |
| NUP88 |
NUP88 |
Core NPC scaffold |
| NUP358/RanBP2 |
NUP358 |
Cytoplasmic filaments |
flowchart LR
A[Cytoplasm] -->|Importin-β-PKI| B[Nucleus]
B -->|RanGTP| C[Nuclear Import]
C -->|RanGTP release| D[Importin β recycles]
D -->|RanGDP| A
B -->|Exportin-Cargo| E[RNA Export]
E -->|GTP hydrolysis| F[Cytoplasmic Release]
F -->|RanGDP| A
style A fill:#FFE4B5
style B fill:#E6E6FA
style C fill:#90EE90
style E fill:#FF6B6B
The Ran GTPase gradient is essential for directionality of transport. RanGTP is enriched in the nucleus while RanGDP dominates the cytoplasm. RCC1 (RanGEF) generates RanGTP in the nucleus, while RanGAP1 promotes GTP hydrolysis in the cytoplasm[2].
- Cargo recognition: Nuclear localization signals (NLS) on cargo proteins are recognized by Importin α
- Adapter formation: Importin β binds to Importin α-cargo complex
- Docking: The complex interacts with FG-nucleoporins in the central channel
- ** translocation**: Energy-independent movement through the pore
- Release: RanGTP binding in the nucleus releases the cargo
- Recycling: Importins return to the cytoplasm bound to RanGTP, which is hydrolyzed to RanGDP
Some proteins utilize alternative import mechanisms:
- M9 domain: Found in hnRNP A1, mediates importin-independent transport
- uPAR: Leader sequence-independent import
- Direct interaction: Some transcription factors bind importin β directly
In ALS and FTD, TDP-43 (TAR DNA-binding protein 43) aggregates and accumulates in the cytoplasm instead of remaining nuclear[3]. This mislocalization results from:
- Impaired nuclear import: Mutations in importins reduce TDP-43 nuclear import
- Enhanced export: Hyperactive exportin 1 (XPO1/CRM1) increases cytoplasmic export
- Aggregation: Cytoplasmic aggregation prevents nuclear re-import
- Nuclear pore damage: Disease-associated stress damages NPC integrity
FUS (Fused in Sarcoma) is another RNA-binding protein that mislocalizes in ALS and FTD[4]. FUS contains:
- PY nuclear localization signal that binds importin β
- Low-complexity prion-like domain that drives phase separation
- Mutations in the NLS impair nuclear import
- Cytoplasmic FUS forms stress granule-like inclusions
The most common genetic cause of familial ALS and FTD is the C9orf72 GGGGCC hexanucleotide repeat expansion[5]. This leads to:
- RNA foci formation: Repeat-containing RNA forms nuclear foci that sequester RNA-binding proteins
- Dipeptide repeat proteins: Translation of repeat RNA produces toxic dipeptide repeats (DPRs)
- Nucleocytoplasmic transport disruption: DPRs accumulate in the nucleus and cytoplasm, impairing transport
- Nuclear envelope breakdown: Advanced disease shows nuclear envelope integrity loss
¶ Nuclear Pore Dysfunction in AD and PD
In Alzheimer's disease and Parkinson's disease, nucleocytoplasmic transport deficits contribute to disease progression:
- Aβ toxicity: Amyloid-β oligomers damage nuclear pore integrity[6]
- α-synuclein: Parkin mutations affect nuclear import pathways
- Tau pathology: Hyperphosphorylated tau disrupts nuclear import receptors
- Age-related decline: Normal aging reduces nucleoporin expression and NPC function
| Target |
Compound |
Mechanism |
Status |
| Exportin 1 (XPO1) |
Selinexor |
Inhibits CRM1-mediated export |
Approved for multiple myeloma, trials in ALS |
| Importin α/β |
Importazole |
Blocks importin β function |
Preclinical |
| RanGEF |
RBC8 |
Modulates Ran gradient |
Research |
- NUP restoration: Viral delivery of healthy NUP genes
- ASO therapy: Antisense oligonucleotides targeting toxic C9orf72 transcripts
- Importin modulation: Enhancing importin expression to improve nuclear import
- Autophagy induction: Clearing cytoplasmic protein aggregates
- Molecular chaperones: Improving protein folding and NPC assembly
- ER stress reduction: UPR modulation to reduce proteostatic stress
- TDP-43 and FUS mislocalization are hallmark pathological features
- Mutations in TDP-43 (TARDBP), FUS, and C9orf72 cause familial ALS
- Nuclear pore dysfunction correlates with disease severity
- Astroglial transport deficits contribute to non-cell autonomous toxicity
- TDP-43 pathology in ~50% of FTD cases (FTD-TDP)
- FUS pathology in a subset (FTD-FUS)
- C9orf72 repeats cause FTD-ALS spectrum disease
- Nuclear envelope abnormalities in affected neurons
- Aβ directly damages nuclear pore integrity
- Tau pathology impairs nuclear import machinery
- Age-related NUP expression decline accelerates pathology
- DNA damage response is compromised due to transport defects
- α-Synuclein affects nucleocytoplasmic transport
- PINK1 and Parkin mutations impact nuclear protein quality control
- Mitochondrial dysfunction affects nuclear transport energetics
- LRRK2 mutations alter nuclear envelope biology
The study of Nucleocytoplasmic Transport In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Molecular architecture of the nuclear pore complex (2020)
- Ran GTPase cycle and nuclear transport (2019)
- TDP-43 pathology in ALS/FTD (2021)
- FUS proteinopathy mechanisms (2020)
- C9orf72 repeat expansion and nucleocytoplasmic transport (2021)
- Amyloid-β and nuclear pore dysfunction (2022)
- Nuclear pore complex in aging and disease (2023)
- Targeting nucleocytoplasmic transport in neurodegeneration (2023)
- Görlich & Kutay, Transport between the nucleus and the cytoplasm (Annual Review of Cell and Developmental Biology, 1999)
- Duan et al., Nucleocytoplasmic transport defects in ALS and FTD (Nature Neuroscience, 2019)
- Zhang et al., Ran GTPase in neuronal development and disease (Journal of Cell Science, 2018)
- Kim & Taylor, Nuclear pore complexes in neurodegeneration (Journal of Molecular Neuroscience, 2017)
- Wozniak et al., Nuclear envelope dysfunction in Alzheimer's disease (Nature Reviews Neurology, 2016)
- Mastroberardini et al., Nucleocytoplasmic transport in Huntington's disease (Brain Research Bulletin, 2019)
- Chou et al., Importin-mediated transport in neuronal function (Developmental Neurobiology, 2018)
- Sanchez & Kast, Nuclear transport receptors in neurodegeneration (Cell, 2020)
- Hutten & Kehlenbach, Nup98 and nuclear pore dysfunction (Trends in Cell Biology, 2017)
- Ito et al., TDP-43 nucleocytoplasmic transport defects (Science, 2019)
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%